Standard treatments for pancreatic cancer are often ineffective as they cannot be directly delivered to the tumor.
A promising potential new option for targeted treatment is being studied in a clinical trial intended to investigate its effect on reducing the chances of the cancer spreading and extending survival, while improving quality of life.
Introducing RenovoRx’s Trans-Arterial Micro-Perfusion (RenovoTAMP™)
RenovoTAMP is the Company’s novel therapy platform designed to deliver well-established chemotherapeutic agents for localized treatment of solid cancer tumors and is under investigation to increase survival and improve quality of life. This platform technology will enable physicians to isolate the anatomy and micro-perfuse targeted tissue with small molecule chemotherapy.
The TIGeR-PaC clinical trial is a randomized study utilizing the RenovoTAMP platform to evaluate our first product candidate, RenovoGem™ (intra-arterial gemcitabine in combination with the proprietary RenovoCath® delivery system).* TIGeR-PaC is currently enrolling locally advanced, unresectable pancreatic cancer patients. In clinical studies conducted to date, gemcitabine delivered directly via the pancreatic arteries using the RenovoTAMP platform with its treatment regime was associated with more than half the patients living over two years.**
* RenovoTAMP is additionally compatible with other small molecule chemotherapy drugs
** Rosemurgy, Alexander. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma, Journal of Pancreatic Cancer; Vol. 3, issue 1.
In The News
RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium
* Individual results may vary.